Stock AnalizBillionToOne, Inc. BLLN
Medical Specialities · IPO 2025 · data as of November 13, 2026
BillionToOne, Inc. (BLLN) is a healthcare company listed in the US with a market value of about $5.0B. In the twelve months to September 30, 2026 it had revenue of $437M and net income of $46M, a net margin of 10.5%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 114.3, a price to free cash flow of 148.2, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 65% below the current price.
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $437M | $305M | $153M | $72M |
| Net income | $46M | $7M | -$42M | -$83M |
| Free cash flow | $34M | $16M | -$47M | -$60M |
| EPS (diluted) | $0.92 | $0.14 | $-4.12 | $-8.45 |
| Net margin | 10.5% | 2.4% | -27.2% | -115.3% |
| ROIC | — | 2.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $128.29, 22% above the current price; targets range from $110.00 to $145.00; the consensus rating is “Strong buy”; expected EPS is $1.62 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is BillionToOne’s P/E ratio?
About 114.3, based on the last twelve months of diluted earnings per share (forward P/E about 73.3).
Is BillionToOne stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 65% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does BillionToOne pay a dividend?
Not currently.
Is BillionToOne a good stock to buy?
We do not give buy or sell advice. BillionToOne scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.